LIBERTY, IN, March 06, 2018 -- The Union County Opioid Treatment Center reports two years of success using a device to help people safely withdrawal from opioids. Staff at the treatment center have been installing NSS-2 BRIDGE devices since spring 2016 and more than 200 patients have reaped the benefits.
“No one believes it the first time they hear about it, until they see it work,” said Jeff Mathews, Union County Opioid Treatment Center co-director. “We have never had a BRIDGE that doesn’t significantly reduce a Clinical Opiate Withdrawal Scale (COWS) score, never.”
The BRIDGE device, pioneered by Indiana-based medical technology firm Innovative Health Solutions, Inc. (IHS), is placed behind the ear with micro-needle arrays that percutaneously implant in and around the ear. Research study results show an 84.6 percent reduction of withdrawal symptoms in as little as 60 minutes.
IHS donated BRIDGE devices to the Union County Opioid Treatment Center to help jumpstart a program aimed at combating the community’s growing opioid epidemic. Mathews, his co-director, Alvin Day, and other concerned citizens, knew if the program could work in one of Indiana’s smallest and poorest counties, it could work anywhere.
Autumn Howard was one of the center’s first patients to have the BRIDGE installed. Howard had been addicted to heroin for five years when her father introduced her to the BRIDGE. She went to the center having been withdrawn from heroin for 24 hours, a requirement for all patients who have the BRIDGE installed.
“She was in bad shape,” said Mathews. “Her COWS score was so high, and she was throwing up in a bucket every three minutes. I had the seen the BRIDGE work, but I was skeptical with her.”
One hour after installing the BRIDGE, Mathews’ skepticism faded as Howard’s COWS score dropped from 28 to 4. Howard had the BRIDGE removed four days later and has been clean since.
“The BRIDGE saved my life,” said Howard. “I was in awe. There is no way I could have withdrawn naturally. I had tried before, and I never made it more than a day or two. My life is not perfect, but it is a million times better than it was.”
In November 2017, the BRIDGE received clearance from the US Food and Drug Administration (FDA). Doctors can now prescribe treatment using the device to patients who are in withdrawal, along with patients suffering from post-acute withdrawal symptoms (PAWS). The FDA clearance also means the BRIDGE will be eligible for insurance coverage as soon as states and commercial carriers adopt the technology.
“IHS wants every person who needs it to have access to the BRIDGE and we know without insurance coverage, many of those people won’t be able to afford the technology,” said Brian Carrico, president of IHS. “We’ve seen hundreds of patients, just like Autumn, share their story of success after having the BRIDGE installed. This technology works, it’s one-of-a-kind and it’s saving lives daily.”
Click here for more information about the BRIDGE.
Media Contact: Sarah Holsapple [email protected] 317-662-4336


Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
DeepSeek to Raise AI API Prices as Demand for New Models Surges 



